GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.

Zhang J, Guan X, Kong M, Xia M, Yu Y, Zhang C

Metabolism: clinical and experimental8 Nov 2025Cited by 4 (Europe PMC)

PMID41207615DOI10.1016/j.metabol.2025.156433PepBankPUB-41207615

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

01HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with cardiovascular or renal disease, GLP-1RAs and tirzepatide pooled together significantly reduced the risk of death from any cause versus placebo (RR 0.88).
In plain wordsIn pooled trials of people with heart or kidney disease, GLP-1 drugs including tirzepatide lowered the risk of death from any cause compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseAll-cause death (pooled GLP-1RAs and tirzepatide)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Measurements
RR
0.88 ratio
death from any cause
Source sentences
Summary
GLP-1RAs and tirzepatide also significantly reduced the risk of death from any cause (RR 0.88, 95 % CI 0.84-0.92, P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched (January 2015-July 2025) for RCTs comparing GLP-1RAs or tirzepatide with placebo in patients with cardiovascular or renal disease.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4120761501
02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with cardiovascular or renal disease, GLP-1RAs and tirzepatide pooled together significantly reduced the risk of death from cardiovascular causes versus placebo (RR 0.88).
In plain wordsIn pooled trials of people with heart or kidney disease, GLP-1 drugs including tirzepatide lowered the risk of heart-related death compared with placebo.
Peptide
Tirzepatide
Outcome
DecreaseCardiovascular death (pooled GLP-1RAs and tirzepatide)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Measurements
RR
0.88 ratio
death from cardiovascular causes
Source sentences
Summary
and death from cardiovascular causes (RR 0.88, 95 % CI 0.83-0.93, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched (January 2015-July 2025) for RCTs comparing GLP-1RAs or tirzepatide with placebo in patients with cardiovascular or renal disease.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4120761502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.